Compare Humana Inc (HUM) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs MasterCard Inc — how do they compare? Humana Inc trades at $406.89 (market cap $47.81B), while MasterCard Inc trades at $541.26 (market cap $483.71B). The key difference: MasterCard Inc is far larger — about 10.1× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| HUM | MA | |
|---|---|---|
Market Cap | $47.81B | $483.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $598.96 |
52-Week Low | $163.67 | $471.55 |
Enterprise Value | $56.85B | $494.45B |
Dividend Yield | 0.89% | 0.64% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Mastercard (MA) trades at $541.40, down 0.4% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue growth remains solid, climbing to $32.79 billion in 2025, while maintaining high net income margins above 45%. Recent news highlights Mastercard's AI initiatives in ASEAN and commitment to financial inclusion, targeting 500 million more underbanked individuals by 2030.
The investment outlook is positive, driven by consistent earnings outperformance, expanding profit margins, and a dominant market position. Risks include competitive pressures from emerging payment technologies like stablecoins and elevated valuation multiples. Analyst consensus is strongly bullish with a $634.27 price target, suggesting ~17% upside from current levels. Institutional accumulation continues, though investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
